Search results for "Intravenou"

showing 10 items of 390 documents

Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study

2002

A questionnaire-based retrospective clinical and immunological survey was conducted in 73 males with a definite diagnosis of X-linked agammaglobulinemia based on BTK sequence analysis. Forty-four were sporadic and 29 familial cases. At December 2000, the patients' ages ranged from 2 to 33 years; mean age at diagnosis and mean duration of follow-up were 3.5 and 10 years respectively. After the mid-1980s all but 2 were on intravenous immunoglobulin (IVIG) substitution therapy, with residual IgG >500 mg/dl in 94% of the patients at the time of enrollment. Respiratory infections were the most frequent manifestation both prior to diagnosis and over follow-up. Chronic lung disease (CLD) was prese…

Lung DiseasesAdultMalePediatricsmedicine.medical_specialtyGenetic Linkage; Agammaglobulinemia; Humans; Infant Newborn; Protein-Tyrosine Kinases; Child; Child Preschool; X Chromosome; Immunoglobulins Intravenous; Lung Diseases; Adult; Cohort Studies; Chronic Disease; Follow-Up Studies; Adolescent; Mutation; Maleclinical featuresX ChromosomeX-linked agammaglobulinemiaAdolescentGenetic LinkageImmunologyX-linked agammaglobulinemiaImmunoglobulinsX-linked agammaglobulinemia; infections; intravenous immunoglobulin; BTK mutationSepsisCohort StudiesAgammaglobulinemiaImmunopathologyintravenous immunoglobulinEpidemiologymedicineAgammaglobulinaemia Tyrosine KinaseImmunology and AllergyHumansinfectionsChildPreschoolSettore MED/38 - Pediatria Generale e SpecialisticaBTK mutationsbusiness.industryChronic sinusitisInfant NewbornMeningoencephalitisImmunoglobulins IntravenousInfantProtein-Tyrosine Kinasesmedicine.diseaseNewbornBTK mutationagammaglobulinemia; clinical features; BTK mutationsChild PreschoolChronic DiseaseMutationbusinessIntravenousMeningitisCohort studyFollow-Up Studies
researchProduct

MRI of the pulmonary parenchyma.

1999

Imaging of the pulmonary parenchyma represents a unique challenge for MRI. Limited signal is caused by low proton density, susceptibility artifacts, and physiological motion (cardiac pulsation, respiration). Recently, further improvements in MRI techniques have widened the potential for investigations of pulmonary parenchymal disease. These include very short echo times, ultrafast turbo-spin-echo acquisitions, projection reconstruction technique, breathhold imaging, ECG triggering, contrast agents (perfusion imaging, aerosols), sodium imaging, hyperpolarized noble gas imaging, and oxygen enhancement. By using widely available techniques, MRI is helpful in the assessment of (a) acute alveoli…

Lung DiseasesChronic bronchitismedicine.medical_specialtyPulmonary FibrosisContrast MediaAtelectasisPerfusion scanningPulmonary EdemaSensitivity and SpecificityDiagnosis DifferentialMedicineHumansRadiology Nuclear Medicine and imagingLungNeuroradiologyBronchiectasisLungbusiness.industryGeneral MedicinePneumoniamedicine.diseasePulmonary edemaImage EnhancementMagnetic Resonance ImagingPneumoniamedicine.anatomical_structureInjections IntravenousRadiologybusinessPulmonary EmbolismEuropean radiology
researchProduct

Use of intravenous immunoglobulins in Lyell syndrome: Experience of three cases

1996

We present our experience of treatment of the last three cases of Lyell syndrome we have observed. They are three female children, aged between 16 months and 3 years, who showed many features in common with severely burnt patients (large exuding lesions, severe reduction of circulating plasmatic volume, large denuded body surfaces, severe tendency to infections, ...). Therefore, together with the already known scheme of treatment (corticosteroids, correction of hydroelectrolitic balance, antimicrobials), we decided to use intravenous Immunoglobulins (IVIG), which had been already positively used in severely burnt patients. The favorable evolution of the affection in all three cases and the …

Lyell syndromeIntravenous Immunoglobulines (IVIG)Toxic Epidermal Necrolysis (TEN)
researchProduct

THE USE OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (ANAKINRA) IN KAWASAKI DISEASE: A RETROSPECTIVE CASES SERIES

2018

Introduction: Persistent fever and inflammation after infusion of 2g/kg of IVIG, the standard treatment of KD represents a high-risk situation for coronary aneurysms in Kawasaki disease. Identifying patients at risk for IVIG resistance is difficult outside the Asian population, and there remains a critical unmet need to identify an anti-inflammatory treatment that is efficacious in all KD patients. Recent evidence from studies in animals and humans suggest a critical role for interleukin-1 (IL-1) α and β in the pathogenesis of KD. Objectives: To identify the clinical characteristics, reasons for use and response to treatment with anakinra in a retrospective series of patients with Kawasaki …

Male0301 basic medicineBLOCKADEPlacebo-controlled studyCHILDRENSUSCEPTIBILITYPLACEBO-CONTROLLED TRIALPediatricsDOUBLE-BLIND0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieINTERLEUKIN 1 RECEPTOR ANTAGONIST ANAKINRA KAWASAKI DISEASEImmunology and AllergyJUVENILE IDIOPATHIC ARTHRITISChildPediatricAnakinra coronary artery aneurysmPrognosis1107 ImmunologyChild PreschoolDisease ProgressionFemaleVasculitisLife Sciences & BiomedicineHumanmedicine.drugVasculitismusculoskeletal diseasesAutoinflammatory diseaseVasculitimedicine.medical_specialtyMyocarditisPrognosiImmunologyMucocutaneous Lymph Node SyndromeAnakinra coronary artery aneurysms03 medical and health sciencesInternal medicineINFLIXIMABMANAGEMENTmedicineINTRAVENOUS IMMUNOGLOBULINHumansRetrospective Studies030203 arthritis & rheumatologyAnakinraScience & TechnologyKawasaki diseasebusiness.industryInfantReceptors Interleukin-1Retrospective cohort studymedicine.diseaseInfliximabInterleukin 1 Receptor Antagonist Protein030104 developmental biologyInterleukin 1 receptor antagonistKawasaki diseasebusinessInterleukin-1
researchProduct

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

2016

Lymphoid organs, in which antigen presenting cells (APCs) are in close proximity to T cells, are the ideal microenvironment for efficient priming and amplification of T-cell responses. However, the systemic delivery of vaccine antigens into dendritic cells (DCs) is hampered by various technical challenges. Here we show that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands. The LPX protects RNA from extracellular ribonucleases and mediates its efficient uptake and expression of the encod…

Male0301 basic medicineLymphoid TissueT-Lymphocytesmedicine.medical_treatmentStatic ElectricityPriming (immunology)BiologyLymphocyte ActivationAutoantigensCancer VaccinesMice03 medical and health sciences0302 clinical medicineAntigenCancer immunotherapyAntigens NeoplasmInterferonmedicineAnimalsHumansAntigen-presenting cellAntigens ViralMelanomaAntigen PresentationDrug CarriersMembrane GlycoproteinsMultidisciplinaryInnate immune systemClinical Trials Phase I as TopicEffectorMacrophagesRNADendritic CellsMice Inbred C57BLDisease Models Animal030104 developmental biologyToll-Like Receptor 7030220 oncology & carcinogenesisInterferon Type IImmunologyCancer researchNanoparticlesRNAAdministration IntravenousFemaleImmunotherapymedicine.drugNature
researchProduct

Transmission dynamics of HIV-1 subtype B in the Basque Country, Spain

2016

This work was aimed to study the HIV-1 subtype B epidemics in the Basque Country, Spain. 1727 HIV-1 subtype B sequences comprising protease and reverse transcriptase (PR/RT) coding regions, sampled between 2001 and 2008, were analyzed. 156 transmission clusters were detected by means of phylogenetic analyses. Most of them comprised less than 4 individuals and, in total, they included 441 patients. Six clusters comprised 10 or more patients and were further analyzed in order to study their origin and diversification. Four clusters included men who had unprotected homosexual sex (MSM), one group was formed by intravenous drug users (IDUs), and another included both IDUs and people infected th…

Male0301 basic medicineMicrobiology (medical)Time FactorsGenotypePopulationHuman immunodeficiency virus (HIV)HIV InfectionsBiologymedicine.disease_causeMicrobiologyVirusDrug Users03 medical and health sciencesHIV ProteaseDrug Resistance ViralGeneticsmedicineAntiretroviral treatmentHumansProtease inhibitor (pharmacology)Homosexuality MaleeducationMolecular BiologyPhylogenyEcology Evolution Behavior and Systematicseducation.field_of_studyIntravenous drugSequence Analysis RNATransmission (medicine)virus diseases030112 virologyVirologyHIV Reverse TranscriptaseReverse transcriptaseVirus030104 developmental biologyInfectious DiseasesSpainMutationInfeccióHIV-1Infection, Genetics and Evolution
researchProduct

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final …

2016

Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate. Results B…

Male0301 basic medicineOncologyCancer ResearchCD3 ComplexT-Lymphocytesmedicine.medical_treatmentMedizinLymphoma Mantle-CellLymphocyte Activation0302 clinical medicineRecurrenceGermanyhemic and lymphatic diseasesAntibodies BispecificMedicineMolecular Targeted TherapyInfusions IntravenousLymphoma FollicularLymphoma Non-HodgkinRemission InductionMiddle AgedLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleBlinatumomabImmunotherapymedicine.drugAdultmedicine.medical_specialtyLymphoma B-CellMaximum Tolerated DoseAntigens CD19Antineoplastic AgentsDrug Administration Schedule03 medical and health sciencesPharmacokineticsRefractoryInternal medicineHumansAdverse effectbusiness.industryImmunotherapymedicine.diseaseLymphomaSurgery030104 developmental biologyPharmacodynamicsNervous System Diseasesbusiness
researchProduct

Daptomycin for children in clinical practice experience

2016

Data on daptomycin use in the pediatric setting are scanty. We conducted a multicenter, retrospective study on 46 children treated with intravenous daptomycin at a mean dosage of 7.0 mg/kg/d, for a median of 14 days. Three children had adverse events possibly related to daptomycin. The drug was overall well tolerated, even with prolonged treatment.

Male0301 basic medicinePediatricsmedicine.disease_causePediatrics0302 clinical medicinepolycyclic compounds030212 general & internal medicineChildChildrenMedicine (all)OsteomyelitisBacterial InfectionsPerinatology and Child HealthAnti-Bacterial AgentsClinical PracticeInfectious DiseasesChild PreschoolAdministration IntravenousFemalelipids (amino acids peptides and proteins)Children; Daptomycin; Methicillin-resistant Staphylococcus aureus; Osteomyelitis; Sepsis; Pediatrics Perinatology and Child Health; Medicine (all); Microbiology (medical); Infectious DiseasesMethicillin-resistant Staphylococcus aureusmedicine.drugMicrobiology (medical)medicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse Reactions030106 microbiologyChildren; Daptomycin; Methicillin-resistant Staphylococcus aureus; Osteomyelitis; Sepsis;Sepsis03 medical and health sciencesDaptomycinSepsismedicineHumansAdverse effectRetrospective Studiesbusiness.industryOsteomyelitisInfant NewbornInfantRetrospective cohort studybiochemical phenomena metabolism and nutritionbacterial infections and mycosesmedicine.diseaseMethicillin-resistant Staphylococcus aureuscarbohydrates (lipids)Pediatrics Perinatology and Child HealthDaptomycinbusinessProlonged treatment
researchProduct

A preclinical study to model taurine pharmokinetics in the undernourished rat

2018

AbstractMalnutrition is a common feature of chronic and acute diseases, often associated with a poor prognosis, including worsening of clinical outcome, owing, among other factors, to dysfunction of the most internal organs and systems affecting the absorption, metabolism and elimination of drugs and nutrients. Taurine is involved in numerous biological processes and is required in increased amounts in response to pathological conditions. The aim of this study was to describe the behaviour of taurine in well-nourished (WN) rats and to analyse the influence of protein–energy undernutrition on the pharmacokinetic (PK) parameters of taurine, using a PK model. Wistar rats were randomly distribu…

Male0301 basic medicineTaurineTaurinePopulationSerum albuminAdministration OralBiological AvailabilityNutritional StatusMedicine (miscellaneous)PharmacologyExcretionRandom Allocation03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsAnimalsMedicineDistribution (pharmacology)030212 general & internal medicineRats Wistareducationeducation.field_of_studyNutrition and DieteticsDose-Response Relationship DrugbiologyReabsorptionbusiness.industryRatsNONMEM030104 developmental biologychemistryInjections Intravenousbiology.proteinFood DeprivationbusinessBritish Journal of Nutrition
researchProduct

Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain

2019

IF 5.217; International audience; BackgroundOwing to its antibacterial properties, ceftaroline could be attractive for prevention or treatment of bacterial post-neurosurgical meningitis/ventriculitis. However, few data are available concerning its meningeal concentrations.ObjectivesTo investigate ceftaroline CSF pharmacokinetics in ICU patients with an external ventricular drain (EVD).MethodsPatients received a single 600 mg dose of ceftaroline as a 1 h intravenous infusion. Blood and CSF samples were collected before and 0.5, 1, 3, 6, 12 and 24 h after the end of the infusion. Concentrations were assayed in plasma and CSF by LC–MS/MS. A two-step compartmental pharmacokinetic analysis was c…

Male0301 basic medicinemedicine.medical_treatmentprotein bindinginfusion proceduresintensive care unitCerebral VentriclesCerebral VentriculitisPostoperative Complications0302 clinical medicineCerebrospinal fluidTandem Mass SpectrometryPharmacology (medical)030212 general & internal medicineInfusions Intravenousintravenous infusion proceduresmeningitisMiddle AgedAnti-Bacterial Agents3. Good healthIntensive Care UnitsInfectious DiseasesAnesthesiaDrainageceftarolineFemalepharmacokineticsMeningitisAdultMicrobiology (medical)VentriculostomyAdolescent030106 microbiologyCmax[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgerycerebrospinal fluidMeningitis BacterialYoung Adult03 medical and health sciencesPharmacokineticsavian ventriculitismedicineVentriculitisHumansDistribution (pharmacology)plasmaAgedbacterial post-neurosurgical meningitis/ventriculitisPharmacologybusiness.industryModels Theoreticalmedicine.diseaseneurosurgical proceduresCephalosporinsventriculostomybusinessChromatography LiquidExternal ventricular drainJournal of Antimicrobial Chemotherapy
researchProduct